AU2022330892A1 - Camptothecin derivative, and pharmaceutical composition and use thereof - Google Patents

Camptothecin derivative, and pharmaceutical composition and use thereof Download PDF

Info

Publication number
AU2022330892A1
AU2022330892A1 AU2022330892A AU2022330892A AU2022330892A1 AU 2022330892 A1 AU2022330892 A1 AU 2022330892A1 AU 2022330892 A AU2022330892 A AU 2022330892A AU 2022330892 A AU2022330892 A AU 2022330892A AU 2022330892 A1 AU2022330892 A1 AU 2022330892A1
Authority
AU
Australia
Prior art keywords
compound
reaction solution
added
attached form
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022330892A
Other languages
English (en)
Inventor
Yayuan FU
Zhen Li
Lifeng Liu
Jinsheng Ren
Feng Tang
Renhong TANG
Chunyan ZHAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hainan Simcere Zaiming Pharmaceutical Co Ltd
Original Assignee
Simcere Zaiming Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Simcere Zaiming Pharmaceutical Co Ltd filed Critical Simcere Zaiming Pharmaceutical Co Ltd
Publication of AU2022330892A1 publication Critical patent/AU2022330892A1/en
Assigned to HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. reassignment HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. Amend patent request/document other than specification (104) Assignors: SIMCERE ZAIMING PHARMACEUTICAL CO., LTD.
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022330892A 2021-08-19 2022-08-19 Camptothecin derivative, and pharmaceutical composition and use thereof Pending AU2022330892A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202110955364.5 2021-08-19
CN202110955364 2021-08-19
CN202111515247 2021-12-13
CN202111515247.3 2021-12-13
CN202210515797.3 2022-05-12
CN202210515797 2022-05-12
PCT/CN2022/113499 WO2023020605A1 (zh) 2021-08-19 2022-08-19 喜树碱衍生物、其药物组合物及其应用

Publications (1)

Publication Number Publication Date
AU2022330892A1 true AU2022330892A1 (en) 2024-03-21

Family

ID=85239565

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022330892A Pending AU2022330892A1 (en) 2021-08-19 2022-08-19 Camptothecin derivative, and pharmaceutical composition and use thereof

Country Status (8)

Country Link
US (1) US20250270227A1 (https=)
EP (1) EP4389752A4 (https=)
JP (1) JP2024532768A (https=)
KR (1) KR20240049583A (https=)
CN (1) CN117769555A (https=)
AU (1) AU2022330892A1 (https=)
CA (1) CA3228345A1 (https=)
WO (1) WO2023020605A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
WO2023178289A2 (en) * 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
JP2025515988A (ja) * 2022-05-13 2025-05-23 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド カンプトテシン化合物、その調製方法及びその使用
CN119630672B (zh) * 2023-02-23 2026-01-30 一线医药（杭州）有限公司 喜树碱衍生物及其偶联物以及其制备方法和医药用途
KR20240149823A (ko) * 2023-04-06 2024-10-15 주식회사 피노바이오 항암 내성 극복을 위한 신규 캄토테신 유도체 및 이를 포함하는 항체-약물 접합체
CN120858098A (zh) * 2023-05-04 2025-10-28 四川科伦博泰生物医药股份有限公司 稠环化合物及其制备方法和应用
WO2024227439A1 (zh) * 2023-05-04 2024-11-07 四川科伦博泰生物医药股份有限公司 具有靶向作用的偶联物及其制备方法和用途
WO2025153001A1 (zh) * 2024-01-17 2025-07-24 北京泰德制药股份有限公司 含有噻唑[5,4-b]吡啶结构的抗体偶联药物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0540099B1 (en) * 1991-10-29 1996-04-17 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
CN1036197C (zh) * 1992-01-28 1997-10-22 格拉克索有限公司 水溶性喜树碱衍生物
JPH1171280A (ja) * 1997-06-26 1999-03-16 Tanabe Seiyaku Co Ltd 医薬組成物
BR112020020466A2 (pt) * 2018-04-06 2021-01-12 Seattle Genetics, Inc. Conjugados de peptídeo de camptotecina
TWI851577B (zh) * 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
SG11202110922QA (en) 2019-04-26 2021-10-28 Immunogen Inc Camptothecin derivatives
EP4628165A3 (en) * 2021-02-05 2026-03-11 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof
EP4257154A4 (en) * 2021-02-09 2026-04-22 Medilink Therapeutics Suzhou Co Ltd CONJUGATED WITH A BIOACTIVE SUBSTANCE, ITS PREPARATION PROCESS AND ITS USE
IL308734A (en) * 2021-05-27 2024-01-01 Zymeworks Bc Inc Camptothecin analogues, conjugates and methods of use
US20240376120A1 (en) * 2021-09-01 2024-11-14 Shanghai Best-Link Bioscience, Llc Camptothecin compound, preparation method therefor and use thereof
WO2023178289A2 (en) * 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
JP2025515988A (ja) * 2022-05-13 2025-05-23 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド カンプトテシン化合物、その調製方法及びその使用

Also Published As

Publication number Publication date
CA3228345A1 (en) 2023-02-23
US20250270227A1 (en) 2025-08-28
EP4389752A4 (en) 2025-08-20
CN117769555A (zh) 2024-03-26
JP2024532768A (ja) 2024-09-10
WO2023020605A1 (zh) 2023-02-23
KR20240049583A (ko) 2024-04-16
EP4389752A1 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
AU2022330892A1 (en) Camptothecin derivative, and pharmaceutical composition and use thereof
AU2024253142A1 (en) Pyrido[4,3-d]pyrimidine compounds
WO2024009191A1 (en) Pyrido[4,3-d]pyrimidine compounds
WO2024218686A1 (en) Pyrido[4,3-d]pyrimidine compounds
CN119306725A (zh) 一种核苷类化合物及其在治疗猫传染性腹膜炎中的应用
DK2989106T3 (en) CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEINKINASE INHIBITORS
CA2704711C (en) Thiazolopyrimidine p13k inhibitor compounds and methods of use
Kupchan et al. Gnidimacrin and gnidimacrin 20-palmitate, novel macrocyclic antileukemic diterpenoid esters from Gnidia subcordata
AU2019413360B2 (en) Cyclin-dependent kinase inhibitors
CN116199703A (zh) 稠合四环杂环化合物、其制备方法及其在医药上的应用
CN112745335B (zh) 一种三并杂环化合物及其用途
CN114685532A (zh) 大环类化合物及其医药用途
JP5555378B2 (ja) Ｐｉ３ｋｐ１１０デルタに選択的なプリン化合物とその使用の方法
CN112300153B (zh) 一种杂环化合物、药物组合物和用途
CN105461714B (zh) 并环类pi3k抑制剂
JP2011521968A (ja) プリンｐｉ３ｋ阻害剤化合物および使用方法
EP2539337A1 (en) Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
AU2022280845A1 (en) Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines
CN119855812A (zh) 多并环类化合物及其用途
JP2018512062A (ja) Ｔｎｆ阻害剤として有用なヘテロ環式化合物
JP2024546115A (ja) プロテインキナーゼ阻害剤及びその製造方法と応用
AU2023370363A1 (en) Piperidinopyrimidine derivative, preparation method therefor and use thereof in medicine
EP4293029A1 (en) Azaheteroaryl compound, preparation method therefor, and application thereof
CN121969619A (zh) 一种含有噻唑基的哌啶并嘧啶类衍生物、其制备方法及其医药上的应用
HK40107233A (en) Camptothecin derivative, and pharmaceutical composition and use thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO SIMCERE ZAIMING PHARMACEUTICAL CO., LTD.